Qritive and Corista Announce Partnership to Advance the Use of Computational Digital Pathology Workflows with Integrated Image Management

Concord, MA and Singapore

Corista, a leading provider of clinical, research and educational digital pathology image management solutions, and Qritive, a leading developer of artificial intelligence (AI)-powered cancer diagnostics, are announcing a new partnership in digital pathology. Through the partnership, Corista’s DP3® image management platform and Qritive’s artificial intelligence modules will be integrated to help pathologist’s focus their time towards more complex case work.

The combined solution enables computational modules to screen for prostate and colon cancers, quantify IHC markers, and detect lymph node metastasis.

With this integrated solution, pathologists will be able to increase their efficiency by prioritizing and grading specific cases, while improving the detection of difficult to diagnose cancers. This enhanced digital pathology workflow will allow for pre-reviewed AI analysis of digital pathology images utilizing any whole slide image scanning device and laboratory information system (LIS).

Corista’s industry-leading clinical image management system DP3 is DICOM-compliant, enables voice collaborations, remote case review, global consults, integrated image analysis with both in-house and commercially available systems, and a proprietary LIS Connector— all in one platform. Combined with Qritive’s AI modules for prostate, colon, lymph metastasis, and the quantification of IHC markers, the integrated solution will support pathologists in making the highest quality diagnoses, while freeing their time for the review of challenging cases.

“Qritive is pushing new frontiers in pathology with Al that is safe, adaptable, and reliable for clinical use,” said Aneesh Sathe, CEO and Co-founder of Qritive. Mr. Sathe continued to state “Corista’s image management system combined with the assistive power of Qritive’s AI modules is the ideal workbench for pathologists to conduct diagnostics with ease, consistency, and precision.”

“Corista’s DP3 platform was built in conjunction with some of the most respected pathology centers at leading medical centers in the US, specifically for clinical-grade pathology use cases. Today, DP3 is the digital pathology platform of choice for many of the largest medical centers across the country”, said Liz Wingard, CEO and Co-founder of Corista. “Our partnership with Qritive will advance the use of artificial intelligence applications to support the growing demands on pathologists to keep up with the pace of their workloads, and the challenges of cancer diagnosis.”

Read More

About Qritive

Qritive, headquartered in Singapore with operations in the US and India, is transforming digital pathology through advanced AI-powered solutions that support cancer diagnosis and improve health outcomes.

By leveraging cutting-edge deep learning technology, Qritive supports pathologists in the interpretation of pathology assessments and enhances pathology workflows—enabling faster, more accurate diagnoses and reducing time to treatment.

Qritive is committed to empowering healthcare professionals around the world with tools that promote collaboration and high performance, regardless of complexity or distance.

Get in Touch

Want to learn more about our solutions or explore potential collaborations?

Visit www.qritive.com or contact us at info@qritive.com